Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alvotech - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
ALVO
Nasdaq
2830
www.alvotech.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alvotech
Here’s What the Street Thinks About Alvotech (ALVO)
- Apr 20th, 2026 3:30 pm
Alvotech (ALVO) Revenue Surges 21% Year-Over-Year in 2025
- Apr 2nd, 2026 12:36 pm
Alvotech files Annual Report with the SEC
- Mar 30th, 2026 5:58 pm
Alvotech Publishes 2025 Annual Report
- Mar 30th, 2026 5:55 pm
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position
- Mar 26th, 2026 4:26 am
Did Alvotech’s (ALVO) Profitability Turn and Expanding Biosimilar Pipeline Just Recast Its Investment Narrative?
- Mar 20th, 2026 1:06 am
Alvotech Q4 Earnings Call Highlights
- Mar 19th, 2026 7:51 am
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Rising Oil Prices, Reduced Rate-Cut Expectations
- Mar 19th, 2026 6:49 am
Alvotech Q4 2025 and Full Year 2025 Financial Results
- Mar 18th, 2026 4:15 pm
Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Look For
- Mar 18th, 2026 7:18 am
Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Expect
- Mar 17th, 2026 7:18 am
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
- Mar 4th, 2026 1:00 am
Is Alvotech (ALVO) Pricing Make Sense After A 64% One Year Share Price Slump
- Feb 16th, 2026 5:08 am
Alvotech AVT80 Progress And Sandoz Deals Shape Biosimilar Outlook
- Feb 16th, 2026 2:08 am
Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80
- Feb 15th, 2026 2:08 am
Alvotech Announces Increase in Number of Own Shares
- Feb 11th, 2026 9:00 am
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
- Feb 5th, 2026 1:00 am
Alvotech (ALVO): A Bull Case Theory
- Feb 4th, 2026 11:39 am
Assessing Alvotech (ALVO) Valuation After Mixed Short Term Gains And A Steep One Year Decline
- Feb 3rd, 2026 5:08 am
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
- Feb 2nd, 2026 1:00 am
Scroll